tizanidine hydrochloride NDC 70710-1111

NDC codes

FDA NDC Directory

Product NDC (as listed)70710-1111Labeler and product segments. Claims need a package NDC.

Product NDC at billing width70710-1111Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
70710-1111-4	70710111104	10 BLISTER PACK in 1 CARTON (70710-1111-4) / 10 CAPSULE in 1 BLISTER PACKMarketed from Apr 27, 2017
70710-1111-5	70710111105	500 CAPSULE in 1 BOTTLE (70710-1111-5)Marketed from Apr 27, 2017
70710-1111-8	70710111108	150 CAPSULE in 1 BOTTLE (70710-1111-8)Marketed from Apr 27, 2017

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): tizanidine hydrochloride
Generic name (nonproprietary): tizanidine hydrochloride
Active ingredients: Tizanidine hydrochloride — 2 mg/1
Dosage form: Capsule
Route: Oral
Labeler: Zydus Pharmaceuticals (USA) Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 208622
Marketing start: Apr 27, 2017
Listing expires: Dec 31, 2027
Other FDA classes: Adrenergic alpha2-Agonists (Mechanism)
Identifiers: Product ID 70710-1111_a619e873-810c-450b-bd4e-de0541ed3e63SPL ID a619e873-810c-450b-bd4e-de0541ed3e63SPL set ID 146c853c-99a8-4bf3-b1e3-be6876abe6ffRxCUI 485484, 485485, 485486UNII B53E3NMY5C
Pharmacologic class: Central alpha-2 Adrenergic Agonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N470710111104 followed by a unit qualifier and the quantity

Package 70710-1111-04. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Dec 10, 2025.

Indications (excerpt from the label)

Tizanidine capsules are a central alpha-2-adrenergic agonist indicated for the treatment of spasticity. ( 1 ) Tizanidine capsules are indicated for the treatment of spasticity in adults.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 208622

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 208622
Product	Strength	Form · route	Labeler	Product NDC
tizanidine hydrochloride	Tizanidine hydrochloride 4 mg/1	CapsuleOral	Zydus Lifesciences Limited	70771-1068
tizanidine hydrochloride	Tizanidine hydrochloride 2 mg/1	CapsuleOral	Zydus Lifesciences Limited	70771-1067
tizanidine hydrochloride	Tizanidine hydrochloride 4 mg/1	CapsuleOral	Zydus Pharmaceuticals (USA) Inc.	70710-1112
tizanidine hydrochloride	Tizanidine hydrochloride 6 mg/1	CapsuleOral	Zydus Lifesciences Limited	70771-1069
tizanidine hydrochloride	Tizanidine hydrochloride 6 mg/1	CapsuleOral	Zydus Pharmaceuticals (USA) Inc.	70710-1113